Päivi Saavalainen

Päivi Saavalainen

Auto-generated profile, based on publicly available information

Päivi Saavalainen

Folkhälsan Research Center, Biomedicum, Helsinki, Finland; Immunomics Research Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2009 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
EEElisabet Einarsdottir
Elisabet Einarsdottir
LKLotta LE Koskinen
Lotta LE Koskinen
EDEmma Dukes
Emma Dukes
KKKati Kainu
Kati Kainu
SSSari Suomela
Sari Suomela
PSPäivi Saavalainen
Päivi Saavalainen
Background: Association of the interleukin-23 receptor (IL23R) with inflammatory bowel disease (IBD) has been confirmed in several populations. IL23R also associates with psoriasis, suggesting that the gene may be an important candidate for many chronic inflammatory diseases. Methods: We studied association of single-nucleotide variants in IL23R with IBD in Swedish patients, in both Crohn's disease (CD) and ulcerative colitis (UC) subsets. The same genetic variants were also studied in Finnish patients with psoriasis or celiac disease, and in Hungarian and Italian patients with celiac disease. Results: Association of IL23R with IBD was replicated in our Swedish patients, and linkage and association of the IL23R region with psoriasis was found in the Finnish population. The IL23R region was also linked to celiac disease in Finnish families, but no association of IL23R variants with celiac disease was found in the Finnish, Hungarian or Italian samples. Conclusion: Our study is the first to demonstrate association of IL23R with CD and UC in Swedish patients with IBD. It is also the first study to report linkage and association of the IL23R region with psoriasis in the Finnish population. Importantly, this is the first report of linkage of the IL23R region to celiac disease, a chronic inflammatory condition in which IL23R has not been previously implicated.

3 March 2009 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
LKLotta Koskinen
Lotta Koskinen
JRJihane Romanos
Jihane Romanos
KKKatri Kaukinen
Katri Kaukinen
KMKirsi Mustalahti
Kirsi Mustalahti
IKIlma Korponay-Szabo
Ilma Korponay-Szabo
PSPäivi Saavalainen
Päivi Saavalainen

21 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DYDawit A. Yohannes
Dawit A. Yohannes
TFTobias L. Freitag
Tobias L. Freitag
AKAndrea de Kauwe
Andrea de Kauwe
KKKatri Kaukinen
Katri Kaukinen
KKKalle Kurppa
Kalle Kurppa
PSPäivi Saavalainen
Päivi Saavalainen
Celiac disease (CD) patients mount an abnormal immune response to gluten. T-cell receptor (TCR) repertoires directed to some immunodominant gluten peptides have previously been described, but the global immune response to in vivo gluten exposure in CD has not been systematically investigated yet. Here, we characterized signatures associated with gluten directed immune activity and identified gluten-induced T-cell clonotypes from total blood and gut TCR repertoires in an unbiased manner using immunosequencing. CD patient total TCR repertoires showed increased overlap and substantially altered TRBV-gene usage in both blood and gut samples, and increased diversity in the gut during gluten exposure. Using differential abundance analysis, we identified gluten-induced clonotypes in each patient that were composed of a large private and an important public component. Hierarchical clustering of public clonotypes associated with dietary gluten exposure identified subsets of highly similar clonotypes, the most proliferative of which showing significant enrichment for the motif ASS[LF]R[SW][TD][DT][TE][QA][YF] in PBMC repertoires. These results show that CD-associated clonotypes can be identified and that common gluten associated immune response features can be characterized in vivo from total repertoires, with potential use in disease stratification and monitoring.

22 December 2008 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
LKLotta L.E. Koskinen
Lotta L.E. Koskinen
EEElisabet Einarsdottir
Elisabet Einarsdottir
EDEmma Dukes
Emma Dukes
GHGraham A. R. Heap
Graham A. R. Heap
PDPatrick Dubois
Patrick Dubois
PSPäivi Saavalainen
Päivi Saavalainen
Coeliac disease is caused by dietary gluten, triggering a chronic inflammation of the small intestine in genetically predisposed individuals. Recently, a risk locus on chromosome 2q11–q12, harbouring interleukin 18 receptor accessory protein (IL18RAP) and three other genes, was suggested for coeliac disease. IL18 has been shown to play an important role in T helper type 1 activity in coeliac disease, making this locus a highly interesting candidate. In this study, two previously indicated risk variants at the IL18RAP locus (rs13015714 and rs917997) were tested for genetic association in 1638 cases with coeliac disease and 1385 control individuals from the Finnish, Hungarian and Italian populations. The protein expression level of IL18RAP was also compared between risk allele carriers and non-carriers by Western blotting. Furthermore, immunohistochemical analysis was performed to study IL18RAP protein expression in small intestinal biopsies of untreated and treated coeliac patients and controls. We confirmed genetic association and dose effects of variants at the 2q12.1 locus with coeliac disease in the Hungarian population. The GA haplotype of the markers rs13015714 and rs917997 showed the strongest association (P = 0.0001, odds ratio = 1.475, 95% confidence interval 1.21–1.80). Two putative isoforms of IL18RAP were detected and the ratios and total levels of these isoforms may contribute to the aetiology of coeliac disease. Our study supports IL18RAP as a novel predisposing gene for coeliac disease and highlights the need for further functional studies on this relatively unknown gene in coeliac disease pathogenesis.

8 September 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
VYVenla Ylönen
Venla Ylönen
KLKatri Lindfors
Katri Lindfors
MRMarleena Repo
Marleena Repo
HHHeini Huhtala
Heini Huhtala
VFValma Fuchs
Valma Fuchs
KKKalle Kurppa
Kalle Kurppa
Non-biopsy diagnosis of celiac disease is possible in children with anti-transglutaminase 2 antibodies (TGA) > 10× the upper limit of normal (ULN) and positive anti-endomysial antibodies (EMA). Similar criteria have been suggested for adults, but evidence with different TGA assays is scarce. We compared the performance of four TGA tests in the diagnosis of celiac disease in cohorts with diverse pre-test probabilities. Serum samples from 836 adults with either clinical suspicion or family risk of celiac disease were tested with four commercial TGA assays, EmA and celiac disease-associated genetics. The diagnosis was set based on duodenal lesion or, in some cases, using special methods. 137 (57%) patients with clinical suspicion and 85 (14%) of those with family risk had celiac disease. Positive predictive value (PPV) for 10×ULN was 100% in each TGA test. The first non-diagnostic investigations were encountered with ULN 1.0×–5.1× in the clinical cohort and 1.3×–4.9× in the family cohort, respectively. Using the assays’ own cut-offs (1×ULN) the PPVs ranged 84–100%. Serology-based diagnosis of celiac disease was accurate in adults using different commercial kits and pre-test probabilities using 10×ULN. The results also suggest that the ULN threshold for biopsy-omitting approach could be lower.

14 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CJChristopher Jonkergouw
Christopher Jonkergouw
NBNgong Beyeh
Ngong Beyeh
EOEkaterina Osmekhina
Ekaterina Osmekhina
KLKatarzyna Leskinen
Katarzyna Leskinen
STS. Maryamdokht Taimoory
S. Maryamdokht Taimoory
Markus B. LinderMarkus B. Linder
Markus B. Linder
The limited diversity in targets of available antibiotic therapies has put tremendous pressure on the treatment of bacterial pathogens, where numerous resistance mechanisms that counteract their function are becoming increasingly prevalent. Here, we utilize an unconventional anti-virulence screen of host-guest interacting macrocycles, and identify a water-soluble synthetic macrocycle, Pillar[5]arene, that is non-bactericidal/bacteriostatic and has a mechanism of action that involves binding to both homoserine lactones and lipopolysaccharides, key virulence factors in Gram-negative pathogens. Pillar[5]arene is active against Top Priority carbapenem- and third/fourth-generation cephalosporin-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, suppressing toxins and biofilms and increasing the penetration and efficacy of standard-of-care antibiotics in combined administrations. The binding of homoserine lactones and lipopolysaccharides also sequesters their direct effects as toxins on eukaryotic membranes, neutralizing key tools that promote bacterial colonization and impede immune defenses, both in vitro and in vivo. Pillar[5]arene evades both existing antibiotic resistance mechanisms, as well as the build-up of rapid tolerance/resistance. The versatility of macrocyclic host-guest chemistry provides ample strategies for tailored targeting of virulence in a wide range of Gram-negative infectious diseases.